Clinical-stage biopharma company Mind Medicine (MindMed), Inc. (NASDAQ: MNMD) shared its financial results for the full year ended Dec. 31, 2022.

Numbers show solid stability:

CEO and director Robert Barrow said that 2022’s progress sets the stage for what the company hopes will be a “transformational” 2023. 

“Importantly, we believe our financial position provides us with the ability to fund our programs well beyond these key milestones and into the first half of 2025,” stated Barrow. “I am incredibly proud of our team’s achievements, and …

Full story available on